Cargando…
When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection
PURPOSE OF REVIEW: Severe-acute respiratory coronavirus 2 (SARS-CoV-2) has been driving the health care delivery system for over 2 years. With time, many issues related to co-infections in COVID-19 patients are constantly surfacing. There have been numerous reports about various fungal co-infections...
Autor principal: | Pruthi, Harnoor Singh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630809/ https://www.ncbi.nlm.nih.gov/pubmed/36345368 http://dx.doi.org/10.1007/s40588-022-00184-0 |
Ejemplares similares
-
Pathogenesis of Fungal Infections in Cystic Fibrosis
por: Williams, Craig, et al.
Publicado: (2016) -
Differential role of gpaB and sidA gene expressions in relation to virulence in Aspergillus species from patients with invasive aspergillosis
por: Ghods, Nayereh, et al.
Publicado: (2018) -
Elastin increases biofilm and extracellular matrix production of Aspergillus fumigatus
por: Brandão, Ildnay de Souza Lima, et al.
Publicado: (2018) -
Ypd1 Is an Essential Protein of the Major Fungal Pathogen Aspergillus fumigatus and a Key Element in the Phosphorelay That Is Targeted by the Antifungal Drug Fludioxonil
por: Schruefer, Sebastian, et al.
Publicado: (2021) -
Antifungal Exposure and Resistance Development: Defining Minimal Selective Antifungal Concentrations and Testing Methodologies
por: Stevenson, Emily M., et al.
Publicado: (2022)